SPG7 Gene: Its Function, Symptoms, and Diagnosis

SPG7 is a gene that encodes a protein called paraplegin, which works inside mitochondria to keep nerve cells healthy. When both copies of SPG7 carry damaging mutations, the result is a progressive neurological condition most commonly recognized as hereditary spastic paraplegia (HSP), though the range of symptoms extends well beyond leg stiffness. Because the clinical picture can look like cerebellar ataxia, a movement disorder, or even an eye disease depending on which features dominate, SPG7 mutations are increasingly recognized as one of the more common and more confusing causes of adult-onset neurogenetic disease.

What Paraplegin Does Inside Cells

Paraplegin sits in the inner membrane of mitochondria, where it forms part of a molecular machine called the m-AAA protease. This complex acts as a quality-control system: it breaks down misfolded or damaged proteins inside mitochondria and helps assemble the components that mitochondria need to produce energy.¹ When paraplegin is absent or defective, mitochondria accumulate structural abnormalities. In mouse models lacking the SPG7 gene, abnormal mitochondria appear in the tips of long nerve fibers and at synaptic terminals well before any outward signs of disease, and over time these defects lead to swelling and degeneration of the axons themselves.²

This matters because the longest nerve fibers in the body, the ones running from the brain down the spinal cord to the legs and feet, are uniquely vulnerable. They require enormous amounts of energy to shuttle cargo back and forth along their length, and when the mitochondria powering that transport fail, the farthest ends of the fibers degrade first. That pattern, called a distal axonopathy, explains why the legs are almost always affected before anything else.

How SPG7 Disease Is Inherited

SPG7-related disease is classically autosomal recessive, meaning a person needs damaging mutations in both copies of the gene to develop symptoms. Carriers who have one working copy and one mutated copy typically remain unaffected. Hundreds of different SPG7 variants have been reported, but a few crop up repeatedly across populations.

The variant p.Ala510Val deserves special mention. Once dismissed as an innocuous common polymorphism because it shows up in roughly three to four percent of people of British ancestry, it has since been convincingly linked to disease. In a large family study, all four siblings who were homozygous for p.Ala510Val developed neurological symptoms, while their eight unaffected siblings either carried only one copy or had none at all. Researchers now consider it the most common mutation causing adult-onset neurogenetic disease in people of British descent, though its penetrance may be low or its effects mild in some carriers.³ In a Hungarian cohort of 437 patients tested for SPG7 variants, p.Ala510Val was the second most common damaging variant found, and there was evidence it could sometimes exert effects even in a single copy, hinting at possible autosomal dominant behavior in some cases.⁴

That last point is worth flagging because it complicates genetic counseling. The standard advice for recessive conditions is that carriers do not get sick. If certain SPG7 variants can occasionally cause trouble even in a single copy, families may need more careful evaluation than the straightforward recessive model would suggest.

The Symptom Spectrum

SPG7 was originally described as a cause of “pure” hereditary spastic paraplegia: gradually worsening stiffness and weakness in the legs, with little else going on. Over time, clinicians noticed that many patients had a messier picture, and SPG7 disease is now understood to span a broad continuum.

In a study of 241 patients, the average age when symptoms first appeared was about 35, though there was wide variation. At presentation, spasticity dominated in roughly a third of patients, ataxia (problems with balance and coordination) dominated in another third, and about a fifth had both from the start.⁵ The takeaway from that study is that spasticity is the primary driver in SPG7, but cerebellar ataxia is common enough that patients are sometimes diagnosed with an ataxia syndrome first and only later found to carry SPG7 mutations. In Italy, the p.Ala510Val variant alone accounted for about two percent of all adult-onset cerebellar ataxia cases, leading researchers to recommend routine SPG7 testing whenever late-onset pure ataxia shows up without another explanation.⁶

Additional features that appear in the “complex” form of SPG7 disease include:

Optic atrophy: gradual loss of vision from degeneration of the optic nerve, which can be severe enough to cause significant visual impairment.⁷
Eye-movement abnormalities: various forms of nystagmus (involuntary rhythmic eye movements), difficulty controlling the accuracy of eye movements, and progressive external ophthalmoplegia, in which the muscles that move the eyes gradually weaken.⁸
Peripheral neuropathy: damage to nerves outside the spinal cord, typically affecting the legs and producing numbness or tingling.
Dysphagia: swallowing difficulties that can develop as the disease progresses.

Not everyone with SPG7 mutations develops the full constellation. Some people live for decades with nothing more than a stiff gait and mild balance trouble, while others accumulate neurological problems across multiple systems. The specific mutations a person carries, whether they are homozygous or compound heterozygous, and likely other genetic and environmental modifiers all shape the outcome.

Why SPG7 Is Easy to Misdiagnose

SPG7 sits at an awkward crossroads in neurological classification. The conditions it causes, spastic paraplegia and cerebellar ataxia, have traditionally been treated as separate diagnostic categories with distinct gene lists. In reality, SPG7 is one of several genes that can produce either phenotype or both simultaneously, blurring the boundary between the two.⁹ A patient who first presents with unsteady walking and a shrinking cerebellum on an MRI may be worked up for spinocerebellar ataxia and tested for a panel of SCA genes. If those come back negative, SPG7 might not be the next thing on the list, even though it should be.

The eye findings add another layer of confusion. Progressive external ophthalmoplegia, the gradual drooping and freezing of eye movements, is a classic hallmark of primary mitochondrial disease. When a patient shows up with that feature alongside muscle biopsy findings of multiple mitochondrial DNA deletions, clinicians may chase a mitochondrial DNA diagnosis rather than looking at SPG7.⁷ The irony is that SPG7 mutations can themselves cause the accumulation of multiple mitochondrial DNA deletions, so the muscle biopsy findings do not actually rule SPG7 in or out.

How SPG7 Disease Is Diagnosed

Diagnosis ultimately rests on genetic testing, but clinical clues and imaging can help narrow the search.

Brain Imaging

The most consistent finding on brain MRI is cerebellar atrophy, visible as shrinkage of the cerebellum. In one Irish cohort, cerebellar atrophy was present on imaging in virtually all patients studied.¹⁰ A rarer but more distinctive MRI finding is hyperintensity of the dentate nuclei, a pair of structures deep within the cerebellum, on T2-weighted sequences.¹¹ Dentate nucleus hyperintensity is not unique to SPG7, but finding it in a patient who also has progressive spasticity and ataxia should prompt the clinician to put SPG7 high on the list.

Genetic Testing

Sequencing the SPG7 gene is straightforward and is usually done as part of a next-generation sequencing panel that covers dozens of HSP and ataxia genes simultaneously. When a pathogenic variant is found, clinical laboratories classify it using standardized criteria. In the Hungarian cohort mentioned earlier, researchers screened 437 patients with spastic ataxia or related symptoms and identified pathogenic or likely pathogenic variants in SPG7 in 58 of them, uncovering 10 clearly damaging variants, five variants of uncertain significance with predicted harmful effects, and one probable risk factor variant.⁴ The study also found multiple mitochondrial DNA deletions and muscle biopsy abnormalities across patients, reinforcing the connection between SPG7 mutations and downstream mitochondrial dysfunction.

A practical point: because p.Ala510Val is common and was once considered a harmless variant, older genetic reports may have filtered it out. If you or a family member have unexplained spastic ataxia and a genetic test from years ago came back negative, it may be worth asking whether the test actually looked at SPG7 and whether p.Ala510Val was reported or dismissed.

Living With SPG7 Disease

There is currently no treatment that halts or reverses the underlying nerve degeneration. Management is multidisciplinary and focused on maintaining function for as long as possible. French clinical guidelines for hereditary spastic paraplegia emphasize that physical rehabilitation through physiotherapy and regular physical activity is the cornerstone of care, with the goal of preventing complications like joint contractures and maintaining mobility. The guidelines also call for psychological support starting from the moment of diagnosis, coordinated follow-up involving neurologists, rehabilitation specialists, physiotherapists, occupational therapists, and social workers.¹²

In practical terms, that means regular stretching and strengthening exercises to counter the progressive tightness in the legs, ankle-foot orthoses or other mobility aids as stiffness worsens, antispasticity medications like baclofen when muscle tone becomes painful or limiting, and periodic reassessment of swallowing and vision if complex features are present. Many people with SPG7-related disease remain ambulatory for years or even decades after symptom onset, though the pace of progression varies widely.

Researchers have been working to develop better tools for tracking disease progression in clinical trials. A multicenter study used wearable sensors and digital gait analysis to identify walking measures that reliably distinguish SPG7 patients from healthy controls and correlate with established disability rating scales.¹³ Having sensitive, objective endpoints like these is essential for future drug trials, because the slow progression of SPG7 disease makes it hard to detect treatment effects using traditional neurological exams alone.

Research Into Potential Treatments

Two lines of experimental work offer cautious reasons for optimism, though neither has reached human trials for SPG7 specifically.

The first involves gene therapy. In paraplegin-deficient mice, researchers injected a viral vector carrying a working copy of the SPG7 gene directly into leg muscles. The virus traveled along nerve fibers to the spinal cord, and six months later, animals that received the treatment showed a significant decrease in the number of damaged axons in their sciatic nerves. One vector type even reduced axonal mitochondrial abnormalities below the levels present at the time of injection, suggesting it did not merely slow the disease but partially reversed existing damage.¹⁴ Translating intramuscular viral gene delivery from mice to humans involves enormous hurdles around dosing, immune responses, and reaching the right cells, but the proof of concept is there.

The second approach targets the downstream mitochondrial dysfunction rather than the gene itself. Using neurons derived from SPG7 patients, researchers screened compounds and found that Bz-423, a molecule that regulates a pore in the mitochondrial membrane, restored mitochondrial membrane potential, corrected the abnormal shape of mitochondria and neurites, and rescued cell viability in patient neurons.¹⁵ This kind of pharmacological strategy has the advantage of being more familiar territory for drug development than gene therapy, though the leap from a dish of neurons to a pill that helps a person walk better is still substantial.

The Eye Connection in Detail

Eye involvement in SPG7 disease deserves a closer look because it is often underappreciated and can sometimes be the presenting feature. SPG7 was initially linked only to leg spasticity with possible cerebellar signs. Over time it became clear that neuro-ophthalmologic problems are a significant part of the picture, ranging from slowly progressive optic nerve degeneration to complex eye-movement disorders including nystagmus, inaccurate saccades, progressive external ophthalmoplegia, and supranuclear vertical palsy, a condition where the eyes lose the ability to look up or down voluntarily.⁸

For patients, this means that an ophthalmologist or neuro-ophthalmologist should be part of the care team, particularly if there are visual complaints or if routine examination picks up subtle eye-movement abnormalities. And for clinicians evaluating someone with unexplained progressive external ophthalmoplegia, SPG7 should be on the differential even if the patient has not yet developed leg symptoms. Progressive external ophthalmoplegia has traditionally been associated with mitochondrial DNA mutations, but SPG7 mutations are now a recognized nuclear gene cause that works through disordered maintenance of mitochondrial DNA, producing the same downstream effect of multiple mitochondrial DNA deletions in muscle tissue.⁷

Variability Between Family Members

One of the more frustrating aspects of SPG7 disease is how different it can look even among siblings who carry the same mutations. In the British family described in the p.Ala510Val study, all four homozygous siblings were affected, but the severity and specific features varied across them. Some had more prominent spasticity; others had more ataxia or additional symptoms. This kind of intrafamilial variability is common in recessive neurogenetic conditions and likely reflects the influence of other genes, lifestyle factors, and chance events during nervous system development and aging.

For families navigating a new SPG7 diagnosis, the implication is that one relative’s disease course is not a reliable predictor of another’s. Two siblings with the same genotype may have meaningfully different trajectories, which makes individual monitoring and personalized rehabilitation plans more important than one-size-fits-all expectations. It also complicates genetic counseling: telling a newly diagnosed person what to expect is harder when the same mutations can produce such different outcomes.

Researchers are actively looking for the modifier genes and biomarkers that explain this variability. The Hungarian cohort study, for instance, documented histological abnormalities and mitochondrial DNA deletions across patients with different variant combinations, providing data that may eventually help predict which patients are at higher risk for rapid progression.⁴ Until those predictive tools mature, close clinical follow-up remains the best way to catch emerging complications early.